

# **Breakthrough Breast Cancer, Breast Cancer Campaign, Breast Cancer Care and Macmillan Cancer Support**

Centre for Health Technology Evaluation  
National Institute for Health and Clinical Excellence  
MidCity Place  
71 High Holborn  
London  
WC1V 6NA

14<sup>th</sup> August 2009

Dear Sir or Madam,

## **Single Technology Appraisal: Lapatinib for women with previously treated advanced or metastatic breast cancer**

Thank you for the invitation to make a submission to the Appraisal Committee regarding the upheld appeal point of whether lapatinib falls within the Supplementary Advice 'Appraising life-extending, end of life treatments'. After having reviewed the appeal submission, the subsequent response of the Appeal Panel and the associated discussions and interpretations of the Supplementary Advice criteria, Breakthrough Breast Cancer, Breast Cancer Campaign, Breast Cancer Care and Macmillan Cancer Support have jointly concluded that we have no additional evidence to submit to the Appraisal Committee in relation to this appeal point.

We were disappointed that the Appraisal Committee were previously unable to approve lapatinib (in combination with capecitabine) for the routine treatment of women with advanced or metastatic breast cancer whose tumors over-express HER2 and, therefore, we are pleased that NICE are now allowing further consideration of the Supplementary Advice. As patient organisations, we would like to emphasise how important it is to offer patients greater treatment choice, especially for patients with metastatic disease who often have limited treatment options.

**Breakthrough Breast Cancer, Breast Cancer Campaign,  
Breast Cancer Care and Macmillan Cancer Support**

If you require further information please contact

[Redacted contact information]

Yours sincerely,

[Redacted signature]

[Redacted signature]